The estimated Net Worth of David S Block is at least $272 Mille dollars as of 1 September 2016. David Block owns over 10,000 units of Cocrystal Pharma Inc stock worth over $271,601 and over the last 10 years David sold COCP stock worth over $0.
David has made over 3 trades of the Cocrystal Pharma Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently David bought 10,000 units of COCP stock worth $4,100 on 1 September 2016.
The largest trade David's ever made was buying 108,696 units of Cocrystal Pharma Inc stock on 25 March 2015 worth over $100,000. On average, David trades about 33,739 units every 105 days since 2015. As of 1 September 2016 David still owns at least 168,696 units of Cocrystal Pharma Inc stock.
You can see the complete history of David Block stock trades at the bottom of the page.
David's mailing address filed with the SEC is 19805 NORTH CREEK PARKWAY, , BOTHELL, WA, 98011.
Over the last 10 years, insiders at Cocrystal Pharma Inc have traded over $2,664,250 worth of Cocrystal Pharma Inc stock and bought 23,366,560 units worth $16,815,201 . The most active insiders traders include Phillip Md Et Al Frost Gamm..., Phillip Md Et Al Frost e Jane Ph D Hsiao. On average, Cocrystal Pharma Inc executives and independent directors trade stock every 113 days with the average trade being worth of $1,616,422. The most recent stock trade was executed by Phillip Md Et Al Frost Gamm... on 4 April 2023, trading 1,015,229 units of COCP stock currently worth $2,000,001.
cocrystal (otcqb:cocp) is a pharmaceutical company seeking to discover novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. cocrystal employs unique technologies and nobel prize winning expertise to create first- and best-in-class antiviral drugs. these technologies, including our nucleoside chemistry expertise and market-focused approach to drug discovery are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. the company has identified promising, preclinical stage antiviral compounds for the unmet medical needs including hepatitis, influenza and norovirus infections. cocrystal has previously received strategic investments from teva pharmaceuticals, opko health (opk), dr. raymond schinazi, brace pharmaceutical, llc, and the frost group.
Cocrystal Pharma Inc executives and other stock owners filed with the SEC include: